Tesamorelin: The FDA-Approved Peptide for Visceral Fat Reduction
Complete guide to Tesamorelin, the only FDA-approved GHRH analog. Learn about its unique benefits for visceral fat, proper use, and what makes it different from other GH peptides.
What is Tesamorelin?
Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) that is FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It's the only GHRH peptide with FDA approval.
Key Facts
- Brand name: Egrifta
- Type: GHRH analog (44 amino acids)
- FDA status: Approved for HIV lipodystrophy
- Unique benefit: Specifically targets visceral fat
- Binds to GHRH receptors in pituitary
- Stimulates GH synthesis and release
- Increases IGF-1 levels
- Promotes lipolysis (fat breakdown)
- Particularly effective on visceral fat
- Visceral fat is metabolically active
- More responsive to GH than subcutaneous fat
- Contains more GH receptors
- Clinical trials show selective reduction
- Average 15-18% reduction in trunk fat
- Maintained over 52 weeks
- Targets the most dangerous fat type
- Improves waist-to-hip ratio
- Improved lipid profiles
- Better insulin sensitivity
- Reduced liver fat
- Potential cognitive benefits
- Improved body image
- Consistent daily timing
- Rotate injection sites (abdomen)
- Allow refrigerated solution to warm slightly
- Empty stomach may enhance absorption
- HIV patients with lipodystrophy
- Excess trunk fat accumulation
- Looking to reduce visceral adiposity
- Metabolic syndrome with central obesity
- Those with stubborn visceral fat
- When lifestyle changes insufficient
- Active malignancy
- Pregnancy/breastfeeding
- Hypersensitivity to tesamorelin or mannitol
- Disruption of pituitary stalk
- Rotate injection sites
- Massage injection area gently
- OTC pain relievers for discomfort
- Usually improve over time
- Hypersensitivity reactions
- Fluid retention issues
- Potential tumor growth (theoretical)
- FDA-approved quality
- Strongest evidence for visceral fat
- Established safety profile
- Once-daily convenience
- 15.2% reduction in trunk fat (vs. 5.0% placebo)
- Maintained at 52 weeks
- Improvements in patient-reported distress
- No significant adverse effects on glucose
- Benefits maintained with continued use
- Fat regain if discontinued
- Safe for extended use
- Periodic reassessment recommended
- Brand name (Egrifta) is expensive
- May require prior authorization
- Specialty pharmacy distribution
- Research versions available
- Baseline and periodic IGF-1 levels
- Glucose monitoring
- Lipid panels
- Body composition assessment
How Tesamorelin Works
Mechanism
Why Visceral Fat Specifically?
Benefits of Tesamorelin
Primary: Visceral Fat Reduction
Clinical trials demonstrate:
Secondary Benefits
Dosing Protocol
FDA-Approved Dosing
| Parameter | Specification | ||
| Dose | 2mg daily | ||
| Timing | Once daily | ||
| Administration | Subcutaneous | ||
| Duration | Ongoing while benefit continues | ||
| Effect | Frequency | ||
| Injection site reactions | 35% | ||
| Joint pain | 17% | ||
| Pain in extremity | 13% | ||
| Peripheral edema | 12% | ||
| Muscle pain | 11% | ||
| Feature | Tesamorelin | CJC-1295 | Sermorelin |
| FDA approved | Yes | No | Previously |
| Visceral fat focus | Strong | Moderate | Moderate |
| Dosing | Daily | Multiple/day | Daily |
| Cost | Higher | Lower | Lower |
| Research | Extensive | Growing | Moderate |
Why Choose Tesamorelin
Clinical Trial Results
Phase 3 Trials
Long-Term Data
Practical Considerations
Cost
Monitoring
Frequently Asked Questions
Q: How long until I see results?
A: Measurable changes in 12-26 weeks; visible changes may take 3-6 months.
Q: Will the fat come back if I stop?
A: Studies show fat regain upon discontinuation.
Q: Is tesamorelin better than other GH peptides?
A: For visceral fat specifically, it has the strongest evidence. For general GH optimization, others may be comparable.
Q: Can I use it without having HIV?
A: Off-label use occurs, but insurance won't cover non-approved indications.
Conclusion
Tesamorelin stands out as the only FDA-approved GHRH peptide with proven efficacy for visceral fat reduction. While more expensive than research peptides, its established safety profile and clinical evidence make it an important option for those specifically targeting dangerous abdominal fat.
Track Your Peptide Protocols
Use PeptIQ to log injections, calculate doses, access our peptide library, and optimize your protocols.
Download PeptIQ Free
